Kalon Aesthetics Splits Leadership for an Aggressive New Growth Phase

DENVER, CO – July 30, 2026 – Kalon Aesthetics, a national platform for aesthetic medicine practices, has announced a significant restructuring of its executive leadership, a move that signals a calculated strategy to accelerate its expansion across the country. The company has appointed Mike Burke, its former President, as the new Chief Executive Officer. Todd DeYoung, who led the company from its infancy to its current multi-state footprint, will transition to the newly created role of Executive Chairman of the Board.

This is not a typical succession plan but a deliberate bifurcation of duties designed to optimize for an aggressive new chapter. The structure leverages Burke's deep operational expertise to manage day-to-day execution and integration, while freeing DeYoung to focus on high-level strategy, strategic partnerships, and, most critically, mergers and acquisitions. It’s a classic private equity-backed playbook for rapid market consolidation, now being deployed in the high-growth, fragmented world of aesthetic medicine.

"I am honored to step into the CEO role at Kalon Aesthetics and build on the exceptional foundation Todd has established," Burke said in the announcement. "Our team is committed to delivering outstanding patient experiences and outcomes, and I look forward to leading this organization into an exciting new chapter."

DeYoung echoed this sentiment, underscoring the strategic nature of the decision. "Mike is the right leader to guide Kalon Aesthetics through this period of growth and expansion," he stated. "As Executive Chairman, I will remain deeply engaged in supporting our strategic direction and long-term vision."

A Deliberate Division of Labor

Mike Burke's appointment as CEO is a clear signal that operational excellence is paramount to Kalon's strategy. With 20 years of experience in scaling complex healthcare operations, Burke is a specialist in the systems that underpin growth. His track record is most notably defined by his decade-long tenure at ClearChoice Dental Implant Centers, a company that shares a similar patient-centric, multi-site model.

During his time at ClearChoice, Burke was instrumental in its expansion from a handful of clinics to a national powerhouse with over 70 locations. As a division president, he managed a portfolio generating over $300 million in annual revenue. His work there involved overseeing what he has previously described as "life-changing procedures" for patients, an experience that directly translates to the emotionally significant and high-stakes world of plastic surgery and aesthetics. This background provides him with a nuanced understanding of how to standardize quality and patient experience across a distributed network of clinics without losing the personal touch.

In his statement, DeYoung specifically highlighted Burke’s "commitment to physician service and commercial acumen" as key qualifications. For a company like Kalon, which partners with existing practices, the ability to serve the needs of its physician-partners is as important as serving the end patient. Burke’s mandate as CEO will be to refine the integration process for new practices, streamline operations, and ensure that the promise of superior support is delivered consistently as the network scales.

The Architect of Expansion Takes a Strategic Perch

Todd DeYoung's move to Executive Chairman is less a step back and more a strategic pivot. Having successfully guided Kalon Aesthetics from its launch in 2023 to a network supporting 30 board-certified plastic surgeons across 14 locations in five states, DeYoung has proven his ability to build from the ground up. His new role leverages that experience for a different purpose: building out, not up.

As Executive Chairman, his focus will shift entirely to board governance, strategic partnerships, and M&A. This frees him from the daily operational demands of a rapidly growing company to concentrate on identifying, negotiating, and closing deals with leading aesthetic practices across the country. In an industry ripe for consolidation, having a seasoned leader dedicated solely to this function provides a significant competitive advantage. He becomes the architect of the company’s future footprint, while Burke acts as the master builder ensuring each new addition is structurally sound.

This division of labor is a hallmark of sophisticated, private equity-backed growth platforms. It allows the company to pursue a dual-track strategy: aggressively acquiring new assets while simultaneously ensuring that the existing platform runs efficiently and maintains its quality standards. DeYoung’s deep industry relationships and strategic vision are now fully dedicated to fueling the M&A engine that will drive Kalon’s next phase of market capture.

Riding the Wave of Consolidation in Aesthetic Medicine

The leadership change at Kalon Aesthetics does not exist in a vacuum. It is a direct reflection of powerful macroeconomic trends reshaping specialty healthcare. The aesthetic medicine market is booming, fueled by demographic shifts, destigmatization, and technological innovation. However, the industry remains highly fragmented, composed largely of small, independent practices. This creates a perfect environment for consolidation, and private equity firms have taken notice.

The "roll-up" strategy—acquiring multiple small practices to create a large, more efficient platform—is well underway in fields like dermatology, dentistry, and veterinary medicine. Kalon is applying this proven model to aesthetics. By centralizing back-office functions like marketing, finance, and human resources, these platforms can achieve economies of scale that are unattainable for independent practitioners. They also provide capital for new technology and expansion, and offer an attractive exit strategy for physicians approaching retirement.

Kalon's promise to preserve "physician leadership, clinical autonomy, and brand identity" is a key differentiator in this competitive landscape. Many top-tier surgeons are protective of the brand and clinical culture they have spent years building. By offering a partnership model rather than a full buyout that erases their identity, Kalon can attract premier practices that might otherwise be hesitant to join a larger network. The success of this new leadership structure will hinge on its ability to maintain that delicate balance, proving that scale and autonomy are not mutually exclusive.